Latest & greatest articles for opioid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on opioid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on opioid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for opioid

141. Opioids Out, Cannabis In Negotiating the Unknowns in Patient Care for Chronic Pain

Opioids Out, Cannabis In Negotiating the Unknowns in Patient Care for Chronic Pain 27802551 2016 12 13 2018 11 13 1538-3598 316 17 2016 Nov 01 JAMA JAMA Opioids Out, Cannabis In: Negotiating the Unknowns in Patient Care for Chronic Pain. 1763-1764 10.1001/jama.2016.13677 Choo Esther K EK Center for Policy and Research in Emergency Medicine, Oregon Health & Science University, Portland. Feldstein Ewing Sarah W SW Department of Psychiatry, Oregon Health & Science University, Portland. Lovejoy (...) Travis I TI Department of Psychiatry, Oregon Health & Science University, Portland3Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, Oregon. eng IK2 HX001516 HX HSRD VA United States K23 DA031881 DA NIDA NIH HHS United States R01 AA023658 AA NIAAA NIH HHS United States 3R01AA023658-02S1 International Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S. United States JAMA 7501160 0098-7484 0 Analgesics 0 Analgesics, Opioid

JAMA2016 Full Text: Link to full Text with Trip Pro

142. Use of biological samples in rehabilitation of persons receiving opioid maintenance treatment: a systematic review

Use of biological samples in rehabilitation of persons receiving opioid maintenance treatment: a systematic review Use of biological samples in rehabilitation of persons receiving opioid mainte-nance treatment: a systematic review - Nasjonalt kunnskapssenter for helsetjenesten Main menu Menu The Knowledge Centre for the Health Services is part of the Norwegian Institute of Public Health since January 1, 2016. For new publications, please go to Search Rapport fra Folkehelseinstituttet (...) - Systematisk oversikt Use of biological samples in rehabilitation of persons receiving opioid mainte-nance treatment: a systematic review Published 22/09/2016 Hov L, Mosdøl A, Ding Y, Strømme H, Vist GE. Use of biological samples in rehabilitation of persons receiving opioid mainte-nance treatment: a systematic review. Rapport fra Folkehelseinstituttet – 2016. ISBN 978-82-8082-767-8 Key messages Opioid maintenance treatment is the most common form of treatment for people with opioid dependence in Norway

The Norwegian Knowledge Centre for the Health Services2016

143. Intravenous nalbuphine 50 microg.kg(-1) is ineffective for opioid-induced pruritus in pediatrics

Intravenous nalbuphine 50 microg.kg(-1) is ineffective for opioid-induced pruritus in pediatrics 27518236 2016 08 13 2016 08 17 2016 08 13 0832-610X 53 11 2006 Nov Canadian journal of anaesthesia = Journal canadien d'anesthesie Can J Anaesth Intravenous nalbuphine 50 µg·kg(-1) is ineffective for opioid-induced pruritus in pediatrics. 1103-10 10.1007/BF03022878 This investigation evaluated the efficacy of nalbuphine in treating postoperative opioid-induced pruritus (Pr) in pediatric patients (...) . After Ethics Board approval, the dual site, tertiary care teaching centre study recruited 212 subjects, age ≥ seven years, who received opioid analgesia postoperatively. A modified, self-report colour analogue scale (CAS) scored pruritus intensity (PrI). Subjects who reported PrI score ≥ 5/10 were randomized to treatment with nalbuphine 50 µg·kg(-1) iv (max 5 mg) or saline placebo. A pruritus intensity difference (PrID) ≥ 50% was considered a positive outcome. Of 260 subjects approached, 212

EvidenceUpdates2016

144. Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable

Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable Traditional opioids for chronic non-cancer pain: untidy, unsatisfactory, and probably unsuitable - Evidently Cochrane Search and hit Go By September 23, 2016 // In this guest blog, Consultant in Pain Medicine Cathy Stannard and pain researcher Andrew Moore discuss some unpalatable truths about traditional opioids for chronic non-cancer pain. What are opioids? There are two main types of opioids (...) . Traditional opioids, which we discuss here, are drugs that work only on opioid receptors in the nervous system; they include morphine, hydromorphone, codeine, hydrocodeine, methadone, oxycodone, fentanyl, and buprenorphine. Some opioids (tramadol, tapentadol) have additional methods of action, and need to be considered separately on another occasion. What is chronic non-cancer pain? If you ignore pain lasting less than three months, and headache, and cancer pain, then what you have left is chronic pain

Evidently Cochrane2016

145. Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment

Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment 27654608 2018 11 13 1538-3598 316 11 2016 Sep 20 JAMA JAMA Physician Capacity to Treat Opioid Use Disorder With Buprenorphine-Assisted Treatment. 1211-1212 10.1001/jama.2016.10542 Stein Bradley D BD RAND Corporation, Pittsburgh, Pennsylvania2University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Sorbero Mark M RAND Corporation, Pittsburgh, Pennsylvania. Dick Andrew W AW RAND Corporation, Boston

JAMA2016 Full Text: Link to full Text with Trip Pro

146. Intranasal and Intramuscular Naloxone for Opioid Overdose in the Pre-Hospital Setting: Comparative Clinical Effectiveness and Cost-Effectiveness

Intranasal and Intramuscular Naloxone for Opioid Overdose in the Pre-Hospital Setting: Comparative Clinical Effectiveness and Cost-Effectiveness Intranasal and Intramuscular Naloxone for Opioid Overdose in the Pre-Hospital Setting: Comparative Clinical Effectiveness and Cost-Effectiveness | CADTH.ca Find the information you need Intranasal and Intramuscular Naloxone for Opioid Overdose in the Pre-Hospital Setting: Comparative Clinical Effectiveness and Cost-Effectiveness Intranasal (...) and Intramuscular Naloxone for Opioid Overdose in the Pre-Hospital Setting: Comparative Clinical Effectiveness and Cost-Effectiveness Published on: September 7, 2016 Project Number: RA0863-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the comparative clinical effectiveness of pre-filled intranasal naloxone versus intramuscular naloxone? What is the comparative clinical effectiveness of pre-filled intranasal naloxone versus naloxone administered

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

147. Buprenorphine/Naloxone Versus Methadone for the Treatment of Opioid Dependence: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines

Buprenorphine/Naloxone Versus Methadone for the Treatment of Opioid Dependence: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines Buprenorphine/Naloxone Versus Methadone for the Treatment of Opioid Dependence: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines | CADTH.ca Find the information you need Buprenorphine/Naloxone Versus Methadone for the Treatment of Opioid Dependence: A Review of Comparative Clinical Effectiveness, Cost (...) -Effectiveness and Guidelines Buprenorphine/Naloxone Versus Methadone for the Treatment of Opioid Dependence: A Review of Comparative Clinical Effectiveness, Cost-Effectiveness and Guidelines Published on: September 2, 2016 Project Number: RD0032-000 Product Line: Research Type: Drug Report Type: Peer-reviewed summary with critical appraisal Result type: Report Question What is the clinical effectiveness of buprenorphine/naloxone compared with methadone for the treatment of patients with opioid dependence

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

148. Unsupervised intake of medicines for individuals in opioid maintenance

Unsupervised intake of medicines for individuals in opioid maintenance Unsupervised intake of medicines for individuals in opioid maintenance - Nasjonalt kunnskapssenter for helsetjenesten Main menu Menu The Knowledge Centre for the Health Services is part of the Norwegian Institute of Public Health since January 1, 2016. For new publications, please go to Search Rapport fra Folkehelseinstituttet - Systematisk oversikt Unsupervised intake of medicines for individuals in opioid maintenance (...) Published 05/09/2016 Hov L, Mosdøl A, Strømme H, Vist G. Unsupervised intake of medicines for individuals in opioid maintenance. Rapport fra Folkehelseinstituttet – 2016. ISBN 978-82-8082-763-0 Key messages Opioid maintenance treatment is the most common form of treatment for people with opioid dependence in Norway. The treatment is often lifelong and constitutes a major interference in everyday life, partly because of frequent supervised administration of the opioid agonist drug, counselling sessions

The Norwegian Knowledge Centre for the Health Services2016

149. New opioid analgesic use and the risk of injurious single-vehicle crashes in drivers aged 50-80 years: A population-based matched case-control study

New opioid analgesic use and the risk of injurious single-vehicle crashes in drivers aged 50-80 years: A population-based matched case-control study 27496939 2016 09 20 2016 09 20 1468-2834 45 5 2016 Sep Age and ageing Age Ageing New opioid analgesic use and the risk of injurious single-vehicle crashes in drivers aged 50-80 years: A population-based matched case-control study. 628-34 10.1093/ageing/afw115 the increasing trend in opioid analgesic use among older drivers has raised concerns about (...) their risk of being involved in car crashes. to investigate if older drivers who started using opioid analgesics have a higher probability of being involved in injurious crashes. population-based matched case-control study. Data from population registers were merged using a personal identity number. Cases were drivers aged 50-80 years responsible for a single vehicle crash between 01.07.05 and 31.12.09 that led to at least one injured passenger (n = 4,445). Four controls were randomly matched to each

EvidenceUpdates2016

150. Prescription opioid abuse: pharmacists’ perspective and response

Prescription opioid abuse: pharmacists’ perspective and response 29354541 2018 11 13 2230-5254 5 2016 Integrated pharmacy research & practice Integr Pharm Res Pract Prescription opioid abuse: pharmacists' perspective and response. 65-73 10.2147/IPRP.S99539 Opioid medication abuse and overdose are major concerns for public health, and a number of responses to address these issues have taken place across the US. Pharmacists and the pharmacy profession have made important contributions as a part (...) of the response to this national crisis. This article provides a brief review of the antecedents, driving forces, and health status of patients involved in the opioid medication and overdose epidemic. This review further discusses pharmacy-based actions that have been undertaken to address this issue, including prescription drug monitoring, take-back, and naloxone training/distribution programs. This review likewise examines current efforts underway in the field to educate practitioners and needed future

Integrated pharmacy research & practice2016 Full Text: Link to full Text with Trip Pro

151. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.

Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial. Background: Hepatitis C virus (HCV) infection is common in persons who inject drugs (PWID). Objective: To evaluate elbasvir-grazoprevir in treating HCV infection in PWID. Design: Randomized, placebo-controlled, double-blind trial. (ClinicalTrials.gov: NCT02105688 ). Setting: Australia, Canada, France, Germany, Israel, the Netherlands, New Zealand, Norway, Spain, Taiwan (...) , the United Kingdom, and the United States. Patients: 301 treatment-naive patients with chronic HCV genotype 1, 4, or 6 infection who were at least 80% adherent to visits for opioid agonist therapy (OAT). Intervention: The immediate-treatment group (ITG) received elbasvir-grazoprevir for 12 weeks; the deferred-treatment group (DTG) received placebo for 12 weeks, no treatment for 4 weeks, then open-label elbasvir-grazoprevir for 12 weeks. Measurements: The primary outcome was sustained virologic response

Annals of Internal Medicine2016

153. Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period

Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period 27400458 2016 09 07 2016 09 07 2168-6114 176 9 2016 Sep 01 JAMA internal medicine JAMA Intern Med Incidence of and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients in the Postoperative Period. 1286-93 10.1001/jamainternmed.2016.3298 Chronic opioid use imposes a substantial burden in terms of morbidity and economic costs. Whether opioid-naive patients undergoing surgery (...) are at increased risk for chronic opioid use is unknown, as are the potential risk factors for chronic opioid use following surgery. To characterize the risk of chronic opioid use among opioid-naive patients following 1 of 11 surgical procedures compared with nonsurgical patients. Retrospective analysis of administrative health claims to determine the association between chronic opioid use and surgery among privately insured patients between January 1, 2001, and December 31, 2013. The data concluded 11

EvidenceUpdates2016

154. Treatment of Opioid-Use Disorders.

Treatment of Opioid-Use Disorders. Treatment of Opioid-Use Disorders. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27464203 Format MeSH and Other Data E-mail Subject Additional text E-mail Add to Clipboard (...) Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 28;375(4):357-68. doi: 10.1056/NEJMra1604339. Treatment of Opioid-Use Disorders. 1 . 1 From the Department of Psychiatry, University of California, San Diego, La Jolla. Comment in [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27464203 DOI: [Indexed for MEDLINE] Free full text Publication type MeSH terms Substances Full Text Sources Other Literature

NEJM2016

155. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.

Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial. IMPORTANCE: The effectiveness of buprenorphine treatment of opioid dependence is limited by suboptimal medication adherence, abuse, and diversion. OBJECTIVE: To determine whether 6-month buprenorphine implants are noninferior to daily sublingual buprenorphine as maintenance treatment for opioid-dependent patients with stable (...) buprenorphine plus 4 placebo implants or sublingual placebo plus four 80-mg buprenorphine hydrochloride implants (expected efficacy, 24 weeks). MAIN OUTCOME MEASURE: The primary end point was between-group difference in proportion of responders (≥4 of 6 months without opioid-positive urine test result [monthly and 4 times randomly] and self-report). The noninferiority established for the lower bound of the 95% confidence interval was greater than -0.20 (P < .025). Secondary end points included cumulative

JAMA2016

156. Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines

Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review of the Clinical Effectiveness and Guidelines Crushed Buprenorphine or Buprenorphine-Naloxone for Opioid Dependency: A Review (...) of the Clinical Effectiveness and Guidelines Published on: July 18, 2016 Project Number: RC0794-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of sublingual crushed buprenorphine for treating opioid dependency? What is the clinical effectiveness and safety of sublingual crushed buprenorphine-naloxone for treating opioid dependency? What are the evidence-based guidelines regarding the administration

Canadian Agency for Drugs and Technologies in Health - Rapid Review2016

157. Mitigation Strategies for Opioid Abuse.

Mitigation Strategies for Opioid Abuse. Mitigation Strategies for Opioid Abuse. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406367 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):96. doi: 10.1056/NEJMc1605652. Mitigation Strategies for Opioid Abuse. , . Comment on [N Engl J Med. 2016] [N Engl J Med. 2016] [N Engl J Med. 2016] PMID: 27406367 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text Sources Medical PubMed Commons 0 comments How to cite this comment: Supplemental Content Full text

NEJM2016

158. Mitigation Strategies for Opioid Abuse.

Mitigation Strategies for Opioid Abuse. Mitigation Strategies for Opioid Abuse. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406368 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):95. doi: 10.1056/NEJMc1605652#SA1. Mitigation Strategies for Opioid Abuse. 1 , 1 , 1 . 1 Massachusetts General Hospital, Boston, MA bbearnot@partners.org. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27406368 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text Sources Medical PubMed Commons 0

NEJM2016 Full Text: Link to full Text with Trip Pro

159. Mitigation Strategies for Opioid Abuse.

Mitigation Strategies for Opioid Abuse. Mitigation Strategies for Opioid Abuse. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 27406369 Format MeSH and Other Data E-mail Subject Additional text E-mail Add (...) to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2016 Jul 7;375(1):95-6. doi: 10.1056/NEJMc1605652#SA2. Mitigation Strategies for Opioid Abuse. 1 . 1 PRA Health Sciences, Salt Lake City, UT lrwebstermd@gmail.com. Comment in [N Engl J Med. 2016] Comment on [N Engl J Med. 2016] PMID: 27406369 DOI: [Indexed for MEDLINE] Publication types MeSH terms Substance Full Text Sources Medical PubMed Commons 0 comments

NEJM2016 Full Text: Link to full Text with Trip Pro

160. Naldemedine for opioid-induced constipation in adults

Naldemedine for opioid-induced constipation in adults Naldemedine for opioid-induced constipation in adults Naldemedine for opioid-induced constipation in adults NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Naldemedine for opioid-induced constipation in adults. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon (...) Scanning Review. 2016 Authors' conclusions Opioids are a class of drugs that are commonly prescribed for pain. Constipation is a side effect that affects nearly all patients taking opioid treatment. There has been an increase in the use of opioids to treat chronic pain in recent years. Current treatment for opioid-induced constipation often involves laxatives. But, it has been estimated that 50–80% of people taking laxatives for opioid-induced constipation get only a limited improvement in symptoms

Health Technology Assessment (HTA) Database.2016